Drug profile

The FDA adverse-event record for Milbemycin + Spinosad

42 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Milbemycin + Spinosad. See the species affected, top reactions, and outcomes below.

42
adverse-event reports
14.3%
death-coded share
Dog
most-reported species
15
Vomiting - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
42
Total Reports
6
Deaths Reported
14.3%
Death Rate

Active Ingredients

MilbemycinSpinosad

Administration Routes

OralUnknownTopical

Species Affected

Dog 42

Most Affected Breeds

Maltese 5
Retriever - Labrador 4
Dog (unknown) 4
Terrier - Yorkshire 3
Retriever - Golden 3
Crossbred Canine/dog 2
Chihuahua 1
Terrier - Boston 1
Terrier - Bull - American Pit 1
Bichon Frise 1

Most Reported Reactions

Vomiting 15
Lack of efficacy - NOS 9
Lethargy (see also Central nervous system depression in 'Neurological') 8
Lack of efficacy (ectoparasite) - flea 6
Seizure NOS 6
Diarrhoea 6
Behavioural disorder NOS 4
Anorexia 4
Death by euthanasia 3
PR-LIVER, LESION(S) 3
Pruritus 2
Bloody diarrhoea 2

Outcome Breakdown

Recovered/Normal
16 (39.0%)
Outcome Unknown
12 (29.3%)
Ongoing
7 (17.1%)
Died
3 (7.3%)
Euthanized
3 (7.3%)

Milbemycin + Spinosad Adverse Event Insights

42 reports name Milbemycin + Spinosad; 6 recorded a death outcome (14.3% of reported events, not a population-level mortality rate). Active ingredients: Milbemycin, Spinosad. Administration routes: Oral, Unknown, Topical.

By species: Dog (42 reports). By breed: Maltese (5), Retriever - Labrador (4), Dog (unknown) (4).

Leading clinical signs: Vomiting (15), Lack of efficacy - NOS (9), Lethargy (see also Central nervous system depression in 'Neurological') (8), Lack of efficacy (ectoparasite) - flea (6). Outcome, 41 coded reports: Recovered/Normal leads at 39.0%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.